WithdrawnPhase 2

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Stopped: Study inactivated due to zero accruals

United States0Started 2020-03-01

Plain-language summary

This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients must have a histologically-confirmed diagnosis of CD30- positive/expressing peripheral T-cell lymphoma (PTCL). NOTE: All PTCL subtypes are eligible, except for adult T-cell leukemia/Lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL); ATLL and CTCL are excluded per exclusion criterion below. Examples of eligible subtypes include but are not limited to the following: * AITL: Angioimmunoblastic T-cell lymphoma * EATL: Enteropathy-associated T-cell lymphoma * ENKTL: Extranodal Natural Killer/T-cell Lymphoma * FTCL: Follicular T-cell lymphoma * HSTCL: Hepatosplenic T-cell lymphoma * PTCL-NOS: Peripheral T-cell lymphoma, not otherwise specified * PTCL-TFH: Nodal peripheral T-cell lymphoma with T-follicular helper phenotype * SPTCL: Subcutaneous Panniculitis-like T-cell Lymphoma * ALCL: Anaplastic Large Cell Lymphoma NOTE: CD30-positivity is defined as \>= 1% of cells expressing CD30 as detected by immunohistochemistry (IHC) and determined by local review. * Patients must have received at least one prior line of systemic therapy and must have relapsed disease or secondary refractory disease meeting one of the below criteria: * Disease that relapsed within \> 6 months after completion of frontline therapy; or * Disease that relapsed within any time after completion of secondary/subsequent lines of therapy; or * Disease that was refractory to secondary/subsequent lines of therapy NOTE: Patients who have primary relapsed/refra…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Overall objective response rate (ORR)

Timeframe: Up to 5 years

Trial details

NCT IDNCT04795869

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-15

View on ClinicalTrials.gov More Recurrent Angioimmunoblastic T-Cell Lymphoma trials